Grant Blauvelt
Family · Fort Wayne, INNPI 1477122711
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (52.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 51 manufacturers reported payments, led by Dexcom, Inc. at 44.5% of the total. 2025 is the largest year on record at $10,993, 6.2 times the $1,781 reported in 2021. Among family clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 763 payments — averaging $36.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$12K
- AstraZeneca$2K
- Enterra Medical, Inc.$1K
- Novo Nordisk$1K
- Corcept Therapeutics$1K
- Lilly USA, LLC$1K
- plus $8K from 45 others
What the payments were for
- Consulting fees$5252%
- Speaking & faculty fees$9,52534%
- Travel & lodging$2,96911%
- Food & beverage$14,82353%
- Education$1681%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$11,356
- DEXCOM STELO GLUCOSE BIOSENSOR$6,072
- Strensiq$525
- Kerendia$244
- Korlym$217
- FARXIGA$131
- ZENPEP$124
- Saxenda$124
- AIMOVIG$122
- RYBELSUS$121
- DEXCOM G6 TRANSMITTER$120
- Omnipod$116
- Inspire$115
- SOLIQUA 100/33$110
How this compares
$28,010 in reported general payments places this provider in the 95th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 279 | $436,507 |
| JardianceEmpagliflozin | 255 | $306,629 |
| MounjaroTirzepatide | 177 | $282,193 |
| TrulicityDulaglutide | 43 | $72,704 |
| FarxigaDapagliflozin Propanediol | 52 | $55,387 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 40 | $51,518 |
| Humalog Kwikpen U-100Insulin Lispro | 71 | $44,516 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $37,496 |
| Xultophy 100-3.6Insulin Degludec/Liraglutide | 18 | $35,004 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 147 | $32,630 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $30,319 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $22,238 |
| RybelsusSemaglutide | 20 | $21,724 |
| Novolog FlexpenInsulin Aspart | 48 | $21,303 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 14 | $17,606 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Xultophy 100-3.6, Rybelsus, Novolog | $1,439 | $497,251330 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,249 | $360,920243 claims |
| Boehringer IngelheimJardiance | $504 | $306,629255 claims |
| AstraZenecaFarxiga | $1,694 | $55,38752 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $674 | $17,60614 claims |
| AbbVieSynthroid | $389 | $2,62027 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $76 | $2,115150 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,392 family providers in Indiana.
Other family in Fort Wayne
- Justin BrownFort Wayne$142K
- Tracy JohnsonFort Wayne$68K
- Benjamin GiarmoFort Wayne$21K
- Katarzyna SedlaczekFort Wayne$20K
- Brandy DantzerFort Wayne$18K
- Catherine RobertsFort Wayne$13K
- Adam ZuberFort Wayne$13K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.